HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial.
No Thumbnail Available
Authors
Cartier, Andrea
Milinkovic, Ana
Goodall, Lisa
Mora‐Peris, Borja
Ogaz, Dana
Palfreeman, Adrian
Pereira, Branca
Reeves, Iain
Saunders, John
Sullivan, Ann K.
Check for full-text access
Issue Date
21/05/2025
Type
Journal Article
Language
Keywords
HIV Infections
Alternative Title
Abstract
Objectives: Here we describe HIV seroconversion events in participants of thePrEP Impact trial.Methods: Of 24 268 participants, we reviewed data for the 54 who were diagnosed with HIV during the trial; 11 at baseline.Results: Incidence was low for those diagnosed pre-pandemic at 0.13 per 100person-years, and mainly linked to low self-reported adherence. The emer-gence of drug resistance in participants reporting recent oral PrEP (tenofovirdisoproxil maleate with emtricitabine (TDF/FTC)) exposure was low (whereanalysis results are available, 21% of participants who seroconverted duringtrial participation showed drug resistance).Conclusions: Oral PrEP TDF/FTC is an effective HIV prevention interven-tion. Further data are needed to assess the prevalence and impact of increasingoral PrEP TDF/FTC use on HIV resistance.
Description
Citation
HIV Medicine. 2025; 26(8): 1300-1303.
Publisher
License
Journal
HIV Medicine
Volume
26.0
Issue
8.0